CLINICAL TRIALS PROFILE FOR CIDOFOVIR
⮫ Send this page by email
✉ Email this page to a colleague
« Back to Dashboard
All Clinical Trials for cidofovir
Trial ID
Title
Status
Sponsor
Phase
Start Date
Summary
NCT00000135 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)
Completed
Johns Hopkins Bloomberg School of Public Health
Phase 2/Phase 3
1995-09-01
To evaluate the efficacy and safety of a human anti-CMV monoclonal antibody, MSL-109, as
adjunct therapy for controlling CMV retinitis.
NCT00000142 ↗ Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Completed
Baylor College of Medicine
Phase 2/Phase 3
1994-04-01
To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously
known as HPMPC) for the treatment of retinitis.
NCT00000142 ↗ Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Completed
Icahn School of Medicine at Mount Sinai
Phase 2/Phase 3
1994-04-01
To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously
known as HPMPC) for the treatment of retinitis.
NCT00000142 ↗ Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Completed
Johns Hopkins University
Phase 2/Phase 3
1994-04-01
To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously
known as HPMPC) for the treatment of retinitis.
NCT00000142 ↗ Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Completed
Louisiana State University Health Sciences Center in New Orleans
Phase 2/Phase 3
1994-04-01
To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously
known as HPMPC) for the treatment of retinitis.
NCT00000142 ↗ Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Completed
New Jersey Medical School
Phase 2/Phase 3
1994-04-01
To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously
known as HPMPC) for the treatment of retinitis.
>Trial ID
>Title
>Status
>Phase
>Start Date
>Summary
Clinical Trial Conditions for cidofovir
Condition Name
Condition Name for cidofovir
Intervention
Trials
HIV Infections
15
Cytomegalovirus Retinitis
10
Cytomegalovirus Infections
3
Leukoencephalopathy, Progressive Multifocal
2
[disabled in preview]
0
Subscribe for full access, or try a Trial
Condition MeSH
Condition MeSH for cidofovir
Intervention
Trials
HIV Infections
16
Retinitis
11
Cytomegalovirus Retinitis
11
Carcinoma in Situ
4
[disabled in preview]
0
Subscribe for full access, or try a Trial
Clinical Trial Locations for cidofovir
Trials by Country
Trials by Country for cidofovir
Location
Trials
United States
114
France
14
Belgium
8
United Kingdom
7
Australia
4
Subscribe for full access, or try a Trial
Trials by US State
Trials by US State for cidofovir
Location
Trials
California
12
Texas
11
New York
9
North Carolina
8
Illinois
8
Subscribe for full access, or try a Trial
Clinical Trial Progress for cidofovir
Clinical Trial Phase
Clinical Trial Phase for cidofovir
Clinical Trial Phase
Trials
Phase 4
4
Phase 3
8
Phase 2/Phase 3
3
[disabled in preview]
21
Subscribe for full access, or try a Trial
Clinical Trial Status
Clinical Trial Status for cidofovir
Clinical Trial Phase
Trials
Completed
27
Not yet recruiting
5
Unknown status
5
[disabled in preview]
6
Subscribe for full access, or try a Trial
Clinical Trial Sponsors for cidofovir
Sponsor Name
Sponsor Name for cidofovir
Sponsor
Trials
Gilead Sciences
10
National Institute of Allergy and Infectious Diseases (NIAID)
6
Johns Hopkins Bloomberg School of Public Health
3
[disabled in preview]
7
Subscribe for full access, or try a Trial
Sponsor Type
Sponsor Type for cidofovir
Sponsor
Trials
Other
44
Industry
20
NIH
10
[disabled in preview]
0
Subscribe for full access, or try a Trial
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
